Open-Label Extension Study of Setmelanotide in Patients With a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Rhythm
- 11 Oct 2024 Planned initiation date changed from 4 Oct 2024 to 23 Oct 2024.
- 30 Sep 2024 New trial record